Performance of a transcription-mediated-amplification HIV-1 RNA assay in pooled specimens.
Very limited data exist on the comparative performance of nucleic acid amplification tests (NATs) for the screening of pooled specimens for acute human immunodeficiency virus (HIV) infection. In this study, we compared a transcription-mediated-amplification assay (Procleix HIV-1 Discriminatory Assay, [TMA]) with a branched DNA assay (Bayer Versant HIV-1 RNA 3.0 assay, [bDNA]). After re-testing 1552 samples that were negative for HIV RNA by bDNA, we found one additional positive sample with the TMA assay. Our results suggest that TMA could potentially detect acute HIV infections missed by other technologies.